Literature DB >> 558786

Radioimmunoassay of vinblastine and vincristine.

J D Teale, J M Clough, V Marks.   

Abstract

1 The cytotoxic agent, vinblastine, was conjugated to albumin, using the Mannich reaction. Rabbits immunized with two conjugates, containing differing amounts of hapten, produce antibodies which bound [3H]-vinblastine. 2 Antisera from one rabbit cross-reacted with both vinblastine and vincristine and were used to develop radioimmunoassays for measuring their concentration in plasma. 3 The antisera showed no cross-reactivity with other alkaloids or cytotoxic drugs and provided assays sensitive to a concentration of 2.1 ng vinblastine or 3.8 ng vincristine/ml of plasma added direct to the assay tubes. 4 This is sufficiently sensitive to permit the measurement of plasma vinblastine levels for up to 24 h after the intravenous administration of 15 mg of the drug.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 558786      PMCID: PMC1429006          DOI: 10.1111/j.1365-2125.1977.tb00690.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Radioimmunoassay and saturation analysis. Pharmacology.

Authors:  V Marks; B A Morris; J D Teale
Journal:  Br Med Bull       Date:  1974-01       Impact factor: 4.291

2.  Antibodies to serotonin.

Authors:  N S Ranadive; A H Sehon
Journal:  Can J Biochem       Date:  1967-11

3.  A method for producing specific antisera with small doses of immunogen.

Authors:  J Vaitukaitis; J B Robbins; E Nieschlag; G T Ross
Journal:  J Clin Endocrinol Metab       Date:  1971-12       Impact factor: 5.958

4.  Pharmacological studies with vinblastine in the dog.

Authors:  W A Creasey; A I Scott; C C Wei; J Kutcher; A Schwartz; J C Marsh
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

5.  Lysergic acid diethylamide: radioimmunoassay.

Authors:  A Taunton-Rigby; S E Sher; P R Kelley
Journal:  Science       Date:  1973-07-13       Impact factor: 47.728

  5 in total
  8 in total

1.  A sensitive radioimmunoassay for vincristine and vinblastine.

Authors:  V S Sethi; S S Burton; D V Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity.

Authors:  C R Pinkerton; B McDermott; T Philip; P Biron; C Ardiet; H Vandenberg; M Brunat-Mentigny
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Can severe vincristine neurotoxicity be prevented?

Authors:  Z R Desai; H W Van den Berg; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.

Authors:  H W Van den Berg; Z R Desai; R Wilson; G Kennedy; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Alkaloid production by transformed root cultures of Catharanthus roseus.

Authors:  A J Parr; A C Peerless; J D Hamill; N J Walton; R J Robins; M J Rhodes
Journal:  Plant Cell Rep       Date:  1988-08       Impact factor: 4.570

7.  Radioimmunoassay of bleomycin in plasma and urine.

Authors:  J D Teale; J M Clough; V Marks
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

Review 8.  Progress in Immunoassays of Toxic Alkaloids in Plant-Derived Medicines: A Review.

Authors:  Zhenhui Ren; Huixia Zhang; Zile Wang; Xin Chen; Liu Yang; Haiyang Jiang
Journal:  Toxins (Basel)       Date:  2022-02-23       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.